• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

Natriuretic peptides in heart failure with preserved ejection fraction.

作者信息

Richards A Mark, Januzzi James L, Troughton Richard W

机构信息

Cardiac Department, Cardiovascular Research Institute, National University Heart Centre, National University of Singapore, 1E Kent Ridge Road, NUHS Tower Block, Level 9, Singapore 119228, Singapore; Department of Medicine, Christchurch Heart Institute, University of Otago, Christchurch, 2 Riccarton Avenue, Christchurch 8140, New Zealand.

Cardiac Intensive Care Unit, Massachusetts General Hospital, Harvard Medical School, 55 Fruit Street, Boston, MA 02114, USA.

出版信息

Heart Fail Clin. 2014 Jul;10(3):453-70. doi: 10.1016/j.hfc.2014.04.006. Epub 2014 May 22.

DOI:10.1016/j.hfc.2014.04.006
PMID:24975909
Abstract

Timely diagnosis, early introduction of appropriate treatment, accurate risk stratification, and optimal titration of therapy are all key to the management of acute and chronic heart failure (HF). Plasma concentrations of the cardiac natriuretic peptides (NPs) are valuable aids in each of these elements of care. However, most data are derived from cohorts with undifferentiated HF or HF with reduced ejection fraction (HFREF), and the performance and best application of NPs in HF with preserved ejection fraction (HFPEF) is less certain. This review outlines the evidence for use of NPs in the evaluation and management of HFPEF.

摘要

相似文献

1
Natriuretic peptides in heart failure with preserved ejection fraction.
Heart Fail Clin. 2014 Jul;10(3):453-70. doi: 10.1016/j.hfc.2014.04.006. Epub 2014 May 22.
2
Prognostic value of N-terminal pro C-type natriuretic peptide in heart failure patients with preserved and reduced ejection fraction.N 端 pro B 型利钠肽原在射血分数保留和降低的心衰患者中的预后价值。
Eur J Heart Fail. 2014 Sep;16(9):958-66. doi: 10.1002/ejhf.140. Epub 2014 Jul 31.
3
Biomarker Profiles in Heart Failure Patients With Preserved and Reduced Ejection Fraction.心力衰竭患者保留和降低射血分数的生物标志物特征。
J Am Heart Assoc. 2017 Mar 30;6(4):e003989. doi: 10.1161/JAHA.116.003989.
4
How B-Type Natriuretic Peptide (BNP) and Body Weight Changes Vary in Heart Failure With Preserved Ejection Fraction Compared With Reduced Ejection Fraction: Secondary Results of the HABIT (HF Assessment With BNP in the Home) Trial.B 型利钠肽(BNP)和体重变化在射血分数保留型心力衰竭与射血分数降低型心力衰竭中的差异:HABIT(家庭中 BNP 用于心力衰竭评估)试验的次要结果。
J Card Fail. 2016 Apr;22(4):283-93. doi: 10.1016/j.cardfail.2015.09.014. Epub 2015 Oct 31.
5
B-type natriuretic peptide and prognosis in heart failure patients with preserved and reduced ejection fraction.B 型利钠肽与射血分数保留和降低心力衰竭患者的预后。
J Am Coll Cardiol. 2013 Apr 9;61(14):1498-506. doi: 10.1016/j.jacc.2012.12.044.
6
Changes in natriuretic peptides after acute hospital presentation for heart failure with preserved ejection fraction: A feasible surrogate trial endpoint? A report from the prospective Karen study.射血分数保留的心力衰竭急性入院后利钠肽的变化:一个可行的替代试验终点?来自前瞻性凯伦研究的报告。
Int J Cardiol. 2017 Jan 1;226:65-70. doi: 10.1016/j.ijcard.2016.10.035. Epub 2016 Oct 17.
7
Cardiac natriuretic peptides: new laboratory parameters in heart failure patients.
Clin Lab. 2001;47(5-6):265-77.
8
Comparison of midregional pro-atrial natriuretic peptide with N-terminal pro-B-type natriuretic peptide in predicting survival in patients with chronic heart failure.比较中段心房利钠肽原与N末端B型利钠肽原在预测慢性心力衰竭患者生存率中的作用
J Am Coll Cardiol. 2007 Nov 13;50(20):1973-80. doi: 10.1016/j.jacc.2007.08.012. Epub 2007 Oct 29.
9
Comparison of the diagnostic and prognostic values of B-type and atrial-type natriuretic peptides in acute heart failure.比较 B 型和心房利钠肽在急性心力衰竭中的诊断和预后价值。
Int J Cardiol. 2013 Oct 9;168(4):3404-11. doi: 10.1016/j.ijcard.2013.04.164. Epub 2013 May 14.
10
Fibrosis marker syndecan-1 and outcome in patients with heart failure with reduced and preserved ejection fraction.纤维化标志物 syndecan-1 与射血分数降低和保留的心衰患者的结局。
Circ Heart Fail. 2014 May;7(3):457-62. doi: 10.1161/CIRCHEARTFAILURE.113.000846. Epub 2014 Mar 19.

引用本文的文献

1
How to Use Natriuretic Peptides in Patients with Heart Failure with Non-Reduced Ejection Fraction?心力衰竭伴射血分数未降低患者如何使用利钠肽?
Anatol J Cardiol. 2023 Jun;27(6):308-318. doi: 10.14744/AnatolJCardiol.2023.3297.
2
Inflammation, non-endothelial dependent coronary microvascular function and diastolic function-Are they linked?炎症、非内皮依赖性冠状动脉微血管功能和舒张功能——它们之间是否存在关联?
PLoS One. 2020 Jul 16;15(7):e0236035. doi: 10.1371/journal.pone.0236035. eCollection 2020.
3
Tetranectin, a potential novel diagnostic biomarker of heart failure, is expressed within the myocardium and associates with cardiac fibrosis.
腱糖蛋白,一种潜在的新型心力衰竭诊断生物标志物,在心内膜表达,并与心脏纤维化相关。
Sci Rep. 2020 May 5;10(1):7507. doi: 10.1038/s41598-020-64558-4.
4
Natriuretic Peptides in Heart Failure with Preserved Left Ventricular Ejection Fraction: From Molecular Evidences to Clinical Implications.心力衰竭伴保留射血分数的利钠肽:从分子证据到临床意义。
Int J Mol Sci. 2019 May 28;20(11):2629. doi: 10.3390/ijms20112629.
5
Biomarkers, myocardial fibrosis and co-morbidities in heart failure with preserved ejection fraction: an overview.射血分数保留的心力衰竭中的生物标志物、心肌纤维化和合并症:综述
Arch Med Sci. 2018 Jun;14(4):890-909. doi: 10.5114/aoms.2018.76279. Epub 2018 Jun 11.
6
Biomarkers in Acute Heart Failure - Cardiac And Kidney.急性心力衰竭中的生物标志物——心脏与肾脏
Card Fail Rev. 2015 Oct;1(2):107-111. doi: 10.15420/cfr.2015.1.2.107.